| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4143dc951bbf6712888ff32fa0d332c6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 |
| filingDate |
2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce80183872ad7c2b568d809d82aac1e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8aac09733d77240cfd3846c208995cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_163054b69edc41a551549657f26d274b |
| publicationDate |
2019-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110448558-A |
| titleOfInvention |
A kind of medicine that suppresses the progress of bladder cancer and medicine application thereof |
| abstract |
The invention discloses a medicine for inhibiting the progression of bladder cancer and its medicine application. The medicine comprises: deoxynojirimycin and its derivatives. Deoxynojirimycin and its derivatives can significantly inhibit the migration and invasion of bladder cancer cells in vitro and in vivo, thereby inhibiting the progression of bladder cancer. Since deoxynojirimycin has been proved by clinical trials to be extremely low in toxicity and not metabolized by the liver, it is eliminated as a prototype without producing additional metabolites. Therefore, the compound and its derivatives can be rapidly applied in clinic to improve the quality of life and prognosis of bladder cancer patients. |
| priorityDate |
2019-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |